Stock Events

Stock Events

AC Immune SA 

€1.9740
52
+€0.09+5%Wednesday 16:30

Statistics

Day High
1.9
Day Low
1.86
52W High
2.21
52W Low
1.69
Volume
500
Avg. Volume
-
Mkt Cap
196.27M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 4Expected
Q2 2026
Q3 2026
-0.16
-0.07
0.02
0.11
Expected EPS
-0.16019424280327998
Actual EPS
-0.13842435152

Financials

-1,971.65%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
3.84MRevenue
-75.67MNet Income

Analyst Ratings

$6.07Average Price Target
The highest estimate is ⁦6.07⁩.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMR.XETRA. It's not an investment recommendation.
Amazon
10
AMZN
Apple
9
AAPL
Microsoft
9
MSFT
NVIDIA
9
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap37.49B
Biogen focuses on neurodegenerative diseases, directly competing with AC Immune's Alzheimer's and Parkinson's disease programs.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly has advanced Alzheimer's disease treatments in its pipeline, making it a direct competitor in the neurodegenerative disease space.
Roche
RHHBY
Mkt Cap334.28B
Roche, with its strong focus on neuroscience and Alzheimer's disease treatments, competes in the same therapeutic areas as AC Immune.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a history of developing treatments for Alzheimer's disease, positioning it as a competitor despite shifting focus in recent years.
Novartis
NVS
Mkt Cap303.67B
Novartis has a broad portfolio that includes treatments for neurodegenerative diseases, competing with AC Immune's research and development focus.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie's interest in neurodegenerative diseases, including Alzheimer's and Parkinson's, places it in competition with AC Immune.
Merck
MRK
Mkt Cap368.89B
Merck has been involved in developing treatments for Alzheimer's disease, making it a competitor in the neurodegenerative space.
AnaptysBio
ANAB
Mkt Cap1.44B
AnaptysBio, while focusing on inflammation, also explores treatments for neurodegenerative diseases, positioning it as a competitor.
Ionis Pharmaceuticals
IONS
Mkt Cap7.23B
Ionis Pharmaceuticals' work on RNA-targeted therapies includes neurodegenerative diseases, making it a competitor in the same research area.

About

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Show More
CEO
Martin Zügel
Employees
122
Country
Switzerland
ISIN
CH0329023102
WKN
000A2AR5F

Listings

STU
DE
IMR.STU
MU
DE
IMR.MU
F
DE
IMR.F
XNAS
US
ACIU

0 Comments

Share your thoughts

FAQs

What is AC Immune SA stock price today?▼
The current price of IMR.XETRA is €1.97 EUR — it has increased by +5% in the past 24 hours. Watch AC Immune SA stock price performance more closely on the chart.
What is AC Immune SA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange AC Immune SA stocks are traded under the ticker IMR.XETRA.
What is AC Immune SA market cap?▼
Today AC Immune SA has the market capitalization of 196.27M
When is the next AC Immune SA earnings date?▼
AC Immune SA is going to release the next earnings report on March 18, 2027.
What were AC Immune SA earnings last quarter?▼
IMR.XETRA earnings for the last quarter are -0.14 EUR per share, whereas the estimation was -0.16 EUR resulting in a +13.59% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is AC Immune SA revenue for the last year?▼
AC Immune SA revenue for the last year amounts to 3.84M EUR.
What is AC Immune SA net income for the last year?▼
IMR.XETRA net income for the last year is -75.67M EUR.
How many employees does AC Immune SA have?▼
As of November 8, 2026, the company has 122 employees.
In which sector is AC Immune SA located?▼
AC Immune SA operates in the Health & Wellness sector.
When did AC Immune SA complete a stock split?▼
AC Immune SA has not had any recent stock splits.
Where is AC Immune SA headquartered?▼
AC Immune SA is headquartered in Lausanne, Switzerland.